Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2004.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.
Clin Infect Dis
November 2024
Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Article Synopsis
- Mortality rates among people with HIV significantly dropped after the introduction of combination antiretroviral therapy, particularly between 1999 and 2009, but remained stable from 2010 to 2020.
- The study analyzed data from over 55,000 participants, revealing that AIDS-related deaths were most common in the earlier period, while deaths from non-AIDS-related malignancies increased in the later years.
- Despite the decline in overall mortality, the reduction was not entirely attributed to better immune function or the presence of other risk factors, suggesting other contributing elements may be at play.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
June 2020
From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Background: Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.
Methods: In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily.
TRY plant trait database - enhanced coverage and open access.
Glob Chang Biol
January 2020
Max Planck Institute for Biogeochemistry, Jena, Germany.
Article Synopsis
- Plant traits, which include various characteristics like morphology and physiology, play a crucial role in how plants interact with their environment and impact ecosystems, making them essential for research in areas like ecology, biodiversity, and environmental management.
- The TRY database, established in 2007, has become a vital resource for global plant trait data, promoting open access and enabling researchers to identify and fill data gaps for better ecological modeling.
- Although the TRY database provides extensive data, there are significant areas lacking consistent measurements, particularly for continuous traits that vary among individuals in their environments, presenting a major challenge that requires collaboration and coordinated efforts to address.
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.
J Int AIDS Soc
March 2018
Institute for Global Health, UCL, London, United Kingdom.
Introduction: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) among HIV-positive individuals. We investigated whether such differences exist in the observational D:A:D cohort study.
Methods: Participants were followed from study enrolment until the earliest of death, six months after last visit or February 1, 2015.
Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med
July 2014
The authors' affiliations are listed in the Appendix.
Background: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.
Methods: In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!